References
- Cohen PA, Zakharevich I, Gerona R. Presence of piracetam in cognitive enhancement dietary supplements. JAMA Intern Med. 2020;180(3):458–459.
- Cohen PA, Avula B, Wang YH, et al. Five unapproved drugs found in cognitive enhancement supplements. Neurol Clin Pract. 2021;11(3):e303–e307.
- Cohen PA, Ellison RR, Travis JC, et al. Quantity of phenibut in dietary supplements before and after FDA warnings. Clin Toxicol. 2022;60(4):486–488.
- Avula B, Chittiboyina AG, Sagi S, et al. Identification and quantification of vinpocetine and picamilon in dietary supplements sold in the United States. Drug Test Anal. 2016;8(3–4):334–343.
- Zou JJ, Ji HJ, Wu DW, et al. Bioequivalence and pharmacokinetic comparison of a single 200-mg dose of meclofenoxate hydrochloride capsule and tablet formulations in healthy Chinese adult male volunteers: a randomized sequence, open-label, two-period crossover study. Clin Ther. 2008;30(9):1651–1657.
- Petkov VD, Stancheva SL, Tocuschieva L, et al. Changes in brain biogenic monoamines induced by the nootropic drugs adafenoxate and meclofenoxate and by citicholine (experiments on rats). Gen Pharmac. 1990;21(1):71–75.
- Wood PL, Péloquin A. Increases in choline levels in rat brain elicited by meclofenoxate. Neuropharmacology. 1982;21(4):349–354.
- Marcer D, Hopkins SM. The differential effects of meclofenoxate on memory loss in the elderly. Age Ageing. 1977;6(2):123–131.
- Oliver JE, Restell M. Serial testing in assessing the effect of meclofenoxate on patients with memory defects. Br J Psychiatry. 1967;113(495):219–222.
- Pék G, Fülöp T, Zs.-Nagy I. Gerontopsychological studies using NAI (‘Nürnberger Alters-Inventar’) on patients with organic psychosyndrome (DSM III, category 1) treated with centrophenoxine in a double blind, comparative, randomized clinical trial. Arch Gerontol Geriatr. 1989;9(1):17–30.